HRP20230023T1 - Postupci liječenja infekcije hepatitisom b - Google Patents

Postupci liječenja infekcije hepatitisom b Download PDF

Info

Publication number
HRP20230023T1
HRP20230023T1 HRP20230023TT HRP20230023T HRP20230023T1 HR P20230023 T1 HRP20230023 T1 HR P20230023T1 HR P20230023T T HRP20230023T T HR P20230023TT HR P20230023 T HRP20230023 T HR P20230023T HR P20230023 T1 HRP20230023 T1 HR P20230023T1
Authority
HR
Croatia
Prior art keywords
preparation
oligonucleotide
positions
nucleotides
preparation according
Prior art date
Application number
HRP20230023TT
Other languages
English (en)
Inventor
Martin KOSER
Marc Abrams
Original Assignee
Dicerna Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66173915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20230023(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dicerna Pharmaceuticals, Inc. filed Critical Dicerna Pharmaceuticals, Inc.
Publication of HRP20230023T1 publication Critical patent/HRP20230023T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (15)

1. Oligonukleotid za smanjenje ekspresije površinskog antigena virusa hepatitisa B (HBsAg) mRNA, te oligonukleotid sadrži smisleni lanac koji tvori dupleks regiju s protusmislenim lancem, naznačen time što: se smisleni lanac sastoji od sekvence kako je navedeno u GACAAAAAUCCUCACAAUAAGCAGCCGAAAGGCUGC (SEQ ID NO:9) i sadrži 2'-fluoro modificirane nukleotide na položajima 3, 8-10, 12, 13, i 17, 2'-O-metil modificirane nukleotide na položajima 1, 2, 4-7, 11, 14-16, 18-26, i 31-36, i jednu fosforotioatnu internukleotidnu vezu između nukleotida na položajima 1 i 2, pri čemu je svaki od nukleotida iz -GAAA- sekvence na smislenom lancu konjugiran na jednovalentni GalNac dio, pri čemu -GAAA- sekvenca sadrži strukturu: [image] i protusmisleni lanac se sastoji od sekvence kako je navedeno u UUAUUGUGAGGAUUUUUGUCGG (SEQ ID NO: 6) i sadrži 2'-fluoro modificirane nukleotide na položajima 2, 3, 5, 7, 8, 10, 12, 14, 16, i 19, 2'-O-metil modificirane nukleotide na položajima 1, 4, 6, 9, 11, 13, 15, 17, 18, i 20-22, i pet fosforotioatnih internukleotidnih veza između nukleotida na položajima 1 i 2, između nukleotida na položajima 2 i 3, između nukleotida na položajima 3 i 4, između nukleotida na položajima 20 i 21, i između nukleotida na položajima 21 i 22, pri čemu 5'-nukleotid protusmislenog lanca ima sljedeću strukturu: [image]
2. Pripravak koji sadrži oligonukleotid prema zahtjevu 1 .
3. Pripravak prema zahtjevu 2, naznačen time što sadrži protuion.
4. Pripravak prema zahtjevu 2, naznačen time što sadrži Na+ protuione.
5. Pripravak prema bilo kojem od zahtjeva 2 do 4, naznačen time što sadrži farmaceutski prihvatljiv nosač.
6. Pripravak prema zahtjevu 5, naznačen time što je farmaceutski prihvatljiv nosač otapalo ili disperzijski medij koji sadrži vodu.
7. Pripravak prema bilo kojem od zahtjeva 2 do 6, naznačen time što sadrži pomoćnu tvar.
8. Pripravak prema bilo kojem od zahtjeva 2 do 7, naznačen time što sadrži otopinu soli s fosfatnim puferom.
9. In vitro postupak smanjenja ekspresije površinskog antigena (HBV) virusa hepatitisa B (HBV) u stanici, naznačen time što postupak uključuje isporuku u stanicu oligonukleotida prema zahtjevu 1, ili pripravka prema bilo kojem od zahtjeva 2 do 8.
10. Postupak prema zahtjevu 9, naznačen time što je stanica hepatocit.
11. Oligonukleotid prema zahtjevu 1 ili pripravak prema bilo kojem od zahtjeva 2 do 8, naznačen time što se koristi u postupku liječenja HBV infekcije kod subjekta.
12. Oligonukleotid ili pripravak za upotrebu prema zahtjevu 11, naznačen time što se oligonukleotid ili pripravak daje subjektu potkožno.
13. Oligonukleotid ili pripravak za upotrebu prema zahtjevu 11, naznačen time što se oligonukleotid ili pripravak daje subjektu intravenski.
14. Pripravak za upotrebu prema zahtjevu 13, naznačen time što sadrži farmaceutski prihvatljiv nosač, pri čemu je farmaceutski prihvatljiv nosač otapalo ili disperzijski medij koji sadrži vodu.
15. Oligonukleotid ili pripravak za upotrebu u skladu s bilo kojim od patentnih zahtjeva 11-14, naznačen time što se subjektu također daje učinkovita količina Entekavira.
HRP20230023TT 2017-10-20 2018-10-19 Postupci liječenja infekcije hepatitisom b HRP20230023T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762575358P 2017-10-20 2017-10-20
PCT/US2018/056801 WO2019079781A2 (en) 2017-10-20 2018-10-19 METHODS OF TREATING HEPATITIS B TYPE INFECTIONS
EP18868404.7A EP3684377B1 (en) 2017-10-20 2018-10-19 Methods for treating hepatitis b infection

Publications (1)

Publication Number Publication Date
HRP20230023T1 true HRP20230023T1 (hr) 2023-03-17

Family

ID=66173915

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20230023TT HRP20230023T1 (hr) 2017-10-20 2018-10-19 Postupci liječenja infekcije hepatitisom b

Country Status (28)

Country Link
US (5) US10799524B2 (hr)
EP (2) EP4197544A1 (hr)
JP (2) JP7353276B2 (hr)
KR (1) KR20200083494A (hr)
CN (1) CN111372593B (hr)
AU (1) AU2018351649A1 (hr)
BR (1) BR112020007476A2 (hr)
CA (1) CA3078960A1 (hr)
CL (1) CL2020001061A1 (hr)
CO (1) CO2020005135A2 (hr)
CR (1) CR20200163A (hr)
DK (1) DK3684377T3 (hr)
ES (1) ES2936863T3 (hr)
FI (1) FI3684377T3 (hr)
HR (1) HRP20230023T1 (hr)
HU (1) HUE061122T2 (hr)
IL (2) IL274040B1 (hr)
LT (1) LT3684377T (hr)
MA (1) MA50264B1 (hr)
MX (1) MX2020004060A (hr)
PE (1) PE20220561A1 (hr)
PH (1) PH12020550591A1 (hr)
PL (1) PL3684377T3 (hr)
PT (1) PT3684377T (hr)
RS (1) RS64001B1 (hr)
SG (1) SG11202003488WA (hr)
SI (1) SI3684377T1 (hr)
WO (1) WO2019079781A2 (hr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7353276B2 (ja) 2017-10-20 2023-09-29 ディセルナ ファーマシューティカルズ インコーポレイテッド Ｂ型肝炎感染の治療方法
WO2021067744A1 (en) * 2019-10-02 2021-04-08 Dicerna Pharmaceuticals, Inc. Chemical modifications of small interfering rna with minimal fluorine content
CN114867856A (zh) * 2019-12-19 2022-08-05 豪夫迈·罗氏有限公司 Saraf抑制剂用于治疗乙型肝炎病毒感染的用途
MX2022007908A (es) * 2019-12-24 2022-07-21 Hoffmann La Roche Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
WO2022026387A1 (en) * 2020-07-27 2022-02-03 Aligos Therapeutics, Inc. Hbv binding oligonucleotides and methods of use
IL300340A (en) 2020-08-05 2023-04-01 Hoffmann La Roche Treatment with oligonucleotides in hepatitis B patients
CN114940991B (zh) * 2021-04-13 2023-02-03 厦门甘宝利生物医药有限公司 一种抑制乙型肝炎病毒基因表达的rna抑制剂及其应用
WO2022223515A2 (en) * 2021-04-19 2022-10-27 Novo Nordisk A/S Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression
WO2023083906A2 (en) 2021-11-11 2023-05-19 F. Hoffmann-La Roche Ag Pharmaceutical combinations for treatment of hbv
CA3235672A1 (en) * 2021-11-29 2023-06-01 Shanghai Argo Biopharmaceutical Co., Ltd. Compositions and methods for inhibiting expression of hepatitis b virus (hbv) protein
EP4201947A1 (en) 2021-12-22 2023-06-28 F. Hoffmann-La Roche AG Process for the backbone deprotection of oligonucleotides containing a terminal alkyl phosphonate group
WO2023116764A1 (zh) * 2021-12-23 2023-06-29 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及其用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127446A1 (en) 1992-05-14 2004-07-01 Lawrence Blatt Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
IL151928A0 (en) 2000-03-30 2003-04-10 Whitehead Biomedical Inst Rna sequence-specific mediators of rna interference
JP4095895B2 (ja) 2000-12-01 2008-06-04 マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー．ヴェー． Ｒｎａ干渉を媒介する短鎖ｒｎａ分子
US20050159378A1 (en) 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
WO2003040395A2 (en) 2001-11-07 2003-05-15 Applera Corporation Universal nucleotides for nucleic acid analysis
EP2314691A3 (en) 2002-11-14 2012-01-18 Dharmacon, Inc. Fuctional and hyperfunctional siRNA
CN1257284C (zh) * 2003-03-05 2006-05-24 北京博奥生物芯片有限责任公司 一种体外阻断乙肝病毒表达的方法
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
WO2007030167A1 (en) 2005-09-02 2007-03-15 Nastech Pharmaceutical Company Inc. Modification of double-stranded ribonucleic acid molecules
EP1979485A2 (en) 2006-01-31 2008-10-15 The Board Of Trustees Of The Leland Stanford Junior University Self-complementary parvoviral vectors, and methods for making and using the same
DK2094086T3 (da) * 2006-11-08 2013-11-25 Veritas Bio LLC Indgivelse in vivo af dobbeltstrenget rna til en målcelle
CN101755049B (zh) 2007-05-29 2014-03-12 约翰内斯堡威特沃特斯兰德大学 初级微rna表达盒
ES2708944T3 (es) 2008-09-22 2019-04-12 Dicerna Pharmaceuticals Inc Composiciones y métodos para la inhibición específica de la expresión de genes por DSRNA que tenga modificaciones
EP3067359A1 (en) 2008-09-23 2016-09-14 Scott G. Petersen Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
CA3151965A1 (en) 2008-12-18 2010-07-15 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
EA201290152A1 (ru) * 2009-10-16 2012-12-28 Глаксо Груп Лимитед Антисмысловые ингибиторы вируса гепатита в (hbv)
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
KR102072631B1 (ko) * 2010-08-17 2020-02-03 시르나 쎄러퓨틱스 인코퍼레이티드 짧은 간섭 핵산 （ｓｉＮＡ）을 사용한 Ｂ형 간염 바이러스 （ＨＢＶ） 유전자 발현의 ＲＮＡ 간섭 매개 억제
RU2667524C2 (ru) * 2011-04-21 2018-09-21 Ионис Фармасьютикалз, Инк. Модулирование экспрессии вируса гепатита b (hbv)
CN113430196A (zh) * 2011-06-30 2021-09-24 箭头药业股份有限公司 用于抑制乙型肝炎病毒的基因表达的组合物和方法
WO2013063313A1 (en) 2011-10-25 2013-05-02 Isis Pharmaceuticals, Inc. Antisense modulation of gccr expression
AU2013356383B2 (en) 2012-12-06 2017-08-31 Merck Sharp & Dohme Corp. Disulfide masked prodrug compositions and methods
TW201437368A (zh) * 2012-12-14 2014-10-01 Dicerna Pharmaceuticals Inc 藉由雙股ｒｎａ之ｃｋａｐ５之專一性抑制之方法和組成物
CN103333890B (zh) 2012-12-21 2015-04-15 厦门成坤生物技术有限公司 治疗乙型病毒性肝炎的rna干扰制剂
GB201408623D0 (en) * 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
US20170114341A1 (en) 2014-06-06 2017-04-27 Solstice Biologics, Ltd. Polynucleotide constructs having bioreversible and non-bioreversible groups
CN104059916A (zh) 2014-06-17 2014-09-24 湖北医药学院附属太和医院 乙肝病毒特异性的microRNA样siRNA序列及其用途
WO2016030863A1 (en) * 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
JOP20200092A1 (ar) * 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
EP3865576A1 (en) 2014-12-15 2021-08-18 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids
WO2016183009A2 (en) * 2015-05-08 2016-11-17 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of antithrombin 3 (at3) by double-stranded rna
CA2991639A1 (en) 2015-08-07 2017-02-16 Arrowhead Pharmaceuticals, Inc. Rnai therapy for hepatitis b virus infection
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
HRP20231063T1 (hr) * 2017-10-13 2023-12-22 Novo Nordisk Health Care Ag Postupci i pripravci namijenjeni inhibiranju eksprimiranja ldha
JP7353276B2 (ja) 2017-10-20 2023-09-29 ディセルナ ファーマシューティカルズ インコーポレイテッド Ｂ型肝炎感染の治療方法

Also Published As

Publication number Publication date
CO2020005135A2 (es) 2020-05-15
BR112020007476A2 (pt) 2020-10-27
US11273173B2 (en) 2022-03-15
IL274040A (en) 2020-06-30
CN111372593B (zh) 2024-03-19
RS64001B1 (sr) 2023-03-31
PL3684377T3 (pl) 2023-04-17
RU2020116369A3 (hr) 2022-02-28
CA3078960A1 (en) 2019-04-25
JP2021500025A (ja) 2021-01-07
US20230000895A1 (en) 2023-01-05
SG11202003488WA (en) 2020-05-28
MA50264A (fr) 2020-07-29
EP4197544A1 (en) 2023-06-21
WO2019079781A2 (en) 2019-04-25
US20200338109A1 (en) 2020-10-29
PH12020550591A1 (en) 2021-03-01
CR20200163A (es) 2020-11-02
US11052104B2 (en) 2021-07-06
PT3684377T (pt) 2023-01-31
US20200171069A1 (en) 2020-06-04
US20210283164A1 (en) 2021-09-16
AU2018351649A1 (en) 2020-04-23
JP2023171403A (ja) 2023-12-01
LT3684377T (lt) 2023-03-10
PE20220561A1 (es) 2022-04-13
US20200338108A1 (en) 2020-10-29
IL282881A (en) 2021-06-30
JP7353276B2 (ja) 2023-09-29
EP3684377A4 (en) 2020-12-16
RU2020116369A (ru) 2021-11-22
CN111372593A (zh) 2020-07-03
US10799524B2 (en) 2020-10-13
ES2936863T3 (es) 2023-03-22
HUE061122T2 (hu) 2023-05-28
KR20200083494A (ko) 2020-07-08
FI3684377T3 (fi) 2023-01-31
US11052105B2 (en) 2021-07-06
SI3684377T1 (sl) 2023-05-31
IL274040B1 (en) 2024-04-01
EP3684377B1 (en) 2022-12-07
CL2020001061A1 (es) 2020-10-30
DK3684377T3 (da) 2023-02-13
MA50264B1 (fr) 2023-03-31
EP3684377A2 (en) 2020-07-29
MX2020004060A (es) 2020-07-21
WO2019079781A3 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
HRP20230023T1 (hr) Postupci liječenja infekcije hepatitisom b
JP2018529732A5 (hr)
HRP20231063T1 (hr) Postupci i pripravci namijenjeni inhibiranju eksprimiranja ldha
HRP20192177T1 (hr) Rnai pripravci za virus hepatitisa b (hbv) i postupci njihove upotrebe
MX2020011805A (es) Agentes de iarn para infeccion causada por el virus de la hepatitis b.
IL290566B1 (en) Preparations and methods for preventing lipoprotein A gene expression
HRP20210612T1 (hr) Postupci i pripravci za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk
JP2021052791A5 (hr)
JP2017538679A5 (hr)
RU2016146817A (ru) Композиции и способы модулирования экспрессии ангиопоэтин-подобного белка 3
JP2021500025A5 (hr)
SI2929031T1 (en) PCSK9 IRNA assemblies and procedures for their use
CA2996722A1 (en) Compositions and agents against hepatitis b virus and uses thereof
RU2019119242A (ru) Композиции на основе irna serpina1 и способы их применения
JP2016502858A5 (hr)
RU2021124592A (ru) Способы и композиции для лечения ассоциированного с serpinc1 расстройства
HRP20220607T1 (hr) Terminalno modificirana rna
MX2021009495A (es) Agentes de iarn para infeccion por el virus de la hepatitis b.
RU2012114198A (ru) Модуляция экспрессии гентингтина
HRP20200822T1 (hr) Pripravci i postupci za inhibiciju ekspresije gena alas1
MX2010009195A (es) Rnas ultrapequeños como antagonistas del receptor tipo toll-3.
CN113750112A (zh) 治疗b型肝炎和d型肝炎病毒感染的方法
JP2018533956A5 (hr)
AU2016219052A1 (en) Compositions and methods for modulating RNA
HRP20210139T1 (hr) Sastavi i postupci za korigiranje mišične distrofije donjih udova tipa 2c upotrebom preskakanja egzona